Dr. Peter Black, MD
Claim this profileVancouver Prostate Centre
Studies Bladder Cancer
Studies Transitional Cell Carcinoma
7 reported clinical trials
9 drugs studied
Area of expertise
1Bladder Cancer
Stage I
Stage II
MLH1 positive
2Transitional Cell Carcinoma
Affiliated Hospitals
Clinical Trials Peter Black, MD is currently running
PDT
for Bladder Cancer
This trial tests a new treatment for bladder cancer patients who do not respond to or cannot tolerate standard therapy. The treatment uses a drug called Ruvidar® that is activated by a special light to kill cancer cells in the bladder.
Recruiting1 award Phase 210 criteria
ST-02
for Urothelial Carcinoma
The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor. The main questions this study aims to answer are: 1. Can ST-02 effectively eradicate UTUC by 3 months? 2. Is ST-02 safe for patients with UTUC? Participants in this study will receive ST-02, a new formulation with gemcitabine once weekly for six weeks. Gemcitabine is known to be an effective drug in treating urothelial carcinoma. This new formulation will be instilled directly into the upper urinary tract (renal pelvis) and will allow the chemotherapeutic to work locally for an extended period of time. The administration process will be retrograde (via a small catheter inserted up into the kidney, under anesthesia) or antegrade (via a nephrostomy, in the clinic) once weekly for six weeks. Safety and efficacy will be monitored for up to a year after the initial response assessment.
Recruiting1 award Phase 2 & 3
More about Peter Black, MD
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Peter Black, MD has experience with
- MRI
- MRI Targeted Biopsy
- Standard Of Care
- Ruvidar® (TLD-1433)
- Cxbladder
- Urothelial Cancer Screening Using Urine Tumor DNA Test
Breakdown of trials Peter Black, MD has run
Bladder Cancer
Transitional Cell Carcinoma
Prostate Cancer
Non-Muscle Invasive Bladder Cancer
Blood in Urine
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Black, MD specialize in?
Peter Black, MD focuses on Bladder Cancer and Transitional Cell Carcinoma. In particular, much of their work with Bladder Cancer has involved Stage I patients, or patients who are Stage II.
Is Peter Black, MD currently recruiting for clinical trials?
Yes, Peter Black, MD is currently recruiting for 3 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Peter Black, MD has studied deeply?
Yes, Peter Black, MD has studied treatments such as MRI, MRI Targeted Biopsy, Standard of Care.
What is the best way to schedule an appointment with Peter Black, MD?
Apply for one of the trials that Peter Black, MD is conducting.
What is the office address of Peter Black, MD?
The office of Peter Black, MD is located at: Vancouver Prostate Centre, Vancouver, British Columbia V5Z1M9 Canada. This is the address for their practice at the Vancouver Prostate Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.